Iain S Forrest1,2,3,4, Kumardeep Chaudhary1,3,4,5, Ha My T Vy1,4, Ben O Petrazzini1,4, Shantanu Bafna1,4, Daniel M Jordan1,4, Ghislain Rocheleau1,4, Ruth J F Loos1,4,6, Girish N Nadkarni1,3,5,7, Judy H Cho1,3,4,7, Ron Do1,3,4. 1. The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. 2. Medical Scientist Training Program, Icahn School of Medicine at Mount Sinai, New York, New York. 3. The Bio Me Phenomics Center, Icahn School of Medicine at Mount Sinai, New York, New York. 4. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York. 5. The Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York. 6. The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 7. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Abstract
Importance: Population-based assessment of disease risk associated with gene variants informs clinical decisions and risk stratification approaches. Objective: To evaluate the population-based disease risk of clinical variants in known disease predisposition genes. Design, Setting, and Participants: This cohort study included 72 434 individuals with 37 780 clinical variants who were enrolled in the BioMe Biobank from 2007 onwards with follow-up until December 2020 and the UK Biobank from 2006 to 2010 with follow-up until June 2020. Participants had linked exome and electronic health record data, were older than 20 years, and were of diverse ancestral backgrounds. Exposures: Variants previously reported as pathogenic or predicted to cause a loss of protein function by bioinformatic algorithms (pathogenic/loss-of-function variants). Main Outcomes and Measures: The primary outcome was the disease risk associated with clinical variants. The risk difference (RD) between the prevalence of disease in individuals with a variant allele (penetrance) vs in individuals with a normal allele was measured. Results: Among 72 434 study participants, 43 395 were from the UK Biobank (mean [SD] age, 57 [8.0] years; 24 065 [55%] women; 2948 [7%] non-European) and 29 039 were from the BioMe Biobank (mean [SD] age, 56 [16] years; 17 355 [60%] women; 19 663 [68%] non-European). Of 5360 pathogenic/loss-of-function variants, 4795 (89%) were associated with an RD less than or equal to 0.05. Mean penetrance was 6.9% (95% CI, 6.0%-7.8%) for pathogenic variants and 0.85% (95% CI, 0.76%-0.95%) for benign variants reported in ClinVar (difference, 6.0 [95% CI, 5.6-6.4] percentage points), with a median of 0% for both groups due to large numbers of nonpenetrant variants. Penetrance of pathogenic/loss-of-function variants for late-onset diseases was modified by age: mean penetrance was 10.3% (95% CI, 9.0%-11.6%) in individuals 70 years or older and 8.5% (95% CI, 7.9%-9.1%) in individuals 20 years or older (difference, 1.8 [95% CI, 0.40-3.3] percentage points). Penetrance of pathogenic/loss-of-function variants was heterogeneous even in known disease predisposition genes, including BRCA1 (mean [range], 38% [0%-100%]), BRCA2 (mean [range], 38% [0%-100%]), and PALB2 (mean [range], 26% [0%-100%]). Conclusions and Relevance: In 2 large biobank cohorts, the estimated penetrance of pathogenic/loss-of-function variants was variable but generally low. Further research of population-based penetrance is needed to refine variant interpretation and clinical evaluation of individuals with these variant alleles.
Importance: Population-based assessment of disease risk associated with gene variants informs clinical decisions and risk stratification approaches. Objective: To evaluate the population-based disease risk of clinical variants in known disease predisposition genes. Design, Setting, and Participants: This cohort study included 72 434 individuals with 37 780 clinical variants who were enrolled in the BioMe Biobank from 2007 onwards with follow-up until December 2020 and the UK Biobank from 2006 to 2010 with follow-up until June 2020. Participants had linked exome and electronic health record data, were older than 20 years, and were of diverse ancestral backgrounds. Exposures: Variants previously reported as pathogenic or predicted to cause a loss of protein function by bioinformatic algorithms (pathogenic/loss-of-function variants). Main Outcomes and Measures: The primary outcome was the disease risk associated with clinical variants. The risk difference (RD) between the prevalence of disease in individuals with a variant allele (penetrance) vs in individuals with a normal allele was measured. Results: Among 72 434 study participants, 43 395 were from the UK Biobank (mean [SD] age, 57 [8.0] years; 24 065 [55%] women; 2948 [7%] non-European) and 29 039 were from the BioMe Biobank (mean [SD] age, 56 [16] years; 17 355 [60%] women; 19 663 [68%] non-European). Of 5360 pathogenic/loss-of-function variants, 4795 (89%) were associated with an RD less than or equal to 0.05. Mean penetrance was 6.9% (95% CI, 6.0%-7.8%) for pathogenic variants and 0.85% (95% CI, 0.76%-0.95%) for benign variants reported in ClinVar (difference, 6.0 [95% CI, 5.6-6.4] percentage points), with a median of 0% for both groups due to large numbers of nonpenetrant variants. Penetrance of pathogenic/loss-of-function variants for late-onset diseases was modified by age: mean penetrance was 10.3% (95% CI, 9.0%-11.6%) in individuals 70 years or older and 8.5% (95% CI, 7.9%-9.1%) in individuals 20 years or older (difference, 1.8 [95% CI, 0.40-3.3] percentage points). Penetrance of pathogenic/loss-of-function variants was heterogeneous even in known disease predisposition genes, including BRCA1 (mean [range], 38% [0%-100%]), BRCA2 (mean [range], 38% [0%-100%]), and PALB2 (mean [range], 26% [0%-100%]). Conclusions and Relevance: In 2 large biobank cohorts, the estimated penetrance of pathogenic/loss-of-function variants was variable but generally low. Further research of population-based penetrance is needed to refine variant interpretation and clinical evaluation of individuals with these variant alleles.
Authors: David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki Journal: Hum Genet Date: 2013-07-03 Impact factor: 4.132
Authors: Amy C Sturm; Joshua W Knowles; Samuel S Gidding; Zahid S Ahmad; Catherine D Ahmed; Christie M Ballantyne; Seth J Baum; Mafalda Bourbon; Alain Carrié; Marina Cuchel; Sarah D de Ferranti; Joep C Defesche; Tomas Freiberger; Ray E Hershberger; G Kees Hovingh; Lala Karayan; Johannes Jacob Pieter Kastelein; Iris Kindt; Stacey R Lane; Sarah E Leigh; MacRae F Linton; Pedro Mata; William A Neal; Børge G Nordestgaard; Raul D Santos; Mariko Harada-Shiba; Eric J Sijbrands; Nathan O Stitziel; Shizuya Yamashita; Katherine A Wilemon; David H Ledbetter; Daniel J Rader Journal: J Am Coll Cardiol Date: 2018-08-07 Impact factor: 24.094
Authors: Christopher C Chang; Carson C Chow; Laurent Cam Tellier; Shashaank Vattikuti; Shaun M Purcell; James J Lee Journal: Gigascience Date: 2015-02-25 Impact factor: 6.524
Authors: Robert C Green; Jonathan S Berg; Wayne W Grody; Sarah S Kalia; Bruce R Korf; Christa L Martin; Amy L McGuire; Robert L Nussbaum; Julianne M O'Daniel; Kelly E Ormond; Heidi L Rehm; Michael S Watson; Marc S Williams; Leslie G Biesecker Journal: Genet Med Date: 2013-06-20 Impact factor: 8.822
Authors: Marylyn D Ritchie; Joshua C Denny; Rebecca L Zuvich; Dana C Crawford; Jonathan S Schildcrout; Lisa Bastarache; Andrea H Ramirez; Jonathan D Mosley; Jill M Pulley; Melissa A Basford; Yuki Bradford; Luke V Rasmussen; Jyotishman Pathak; Christopher G Chute; Iftikhar J Kullo; Catherine A McCarty; Rex L Chisholm; Abel N Kho; Christopher S Carlson; Eric B Larson; Gail P Jarvik; Nona Sotoodehnia; Teri A Manolio; Rongling Li; Daniel R Masys; Jonathan L Haines; Dan M Roden Journal: Circulation Date: 2013-03-05 Impact factor: 29.690
Authors: Caroline F Wright; Ben West; Marcus Tuke; Samuel E Jones; Kashyap Patel; Thomas W Laver; Robin N Beaumont; Jessica Tyrrell; Andrew R Wood; Timothy M Frayling; Andrew T Hattersley; Michael N Weedon Journal: Am J Hum Genet Date: 2019-01-18 Impact factor: 11.025
Authors: Shi-Ming Tu; Sunny R Singh; Konstantinos Arnaoutakis; Sindhu Malapati; Sajjad A Bhatti; Aron Y Joon; Omar T Atiq; Louis L Pisters Journal: Cancers (Basel) Date: 2022-07-09 Impact factor: 6.575